Immune checkpoint inhibitors in patients with cancers of unknown primary

Affiliations

• ¹ Gustave Roussy, Départements de Médecine Oncologique, F-94805 Villejuif, France; Université Paris-Saclay, Gustave Roussy, Institut national de la santé et de la recherche médicale (INSERM), U1018 Villejuif, France. Electronic address: [email protected].
• ² Gustave Roussy, Départements de Médecine Oncologique, F-94805 Villejuif, France.
• ³ School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom; Department of Oncology, Guy's & St Thomas' Hospital, London, United Kingdom.
• ⁴ Bristol Medical School, University of Bristol, Bristol, UK.
• ⁵ Department of Oncology, Guy's & St Thomas' Hospital, London, United Kingdom.
• ⁶ Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UK; Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London SE1 9RT, UK; Kent Medway Medical School, University of Kent, Canterbury CT2 7LX, UK; AELIA Organization, 9th Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece.
• ⁷ University of Ioannina, 45110 Ioannina, Greece.